Phenotypic and genotypic analysis of biologically cloned human immunodeficiency virus type 1 isolates from patients treated with zidovudine and lamivudine

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 12, 2002, Pages 4000-4003

  Stoeckli, Thomas C ^a,d   MaWhinney, Samantha ^b   Uy, Jonathan ^a,e   Duan, Chengying ^a   Lu, Jing ^a   Shugarts, David ^a   Kuritzkes, Daniel R ^a,c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d Buergerspital   (Switzerland)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; ZIDOVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; CODON; CORRELATION ANALYSIS; DATA BASE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS MUTATION; ANTIBIOTIC RESISTANCE; CELL CLONE; DRUG EFFECT; GENETICS; ISOLATION AND PURIFICATION; MOLECULAR GENETICS; MUTATION; VIROLOGY;

CLONE CELLS; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MOLECULAR SEQUENCE DATA; MUTATION; PHENOTYPE; REVERSE TRANSCRIPTASE INHIBITORS; ZIDOVUDINE;

EID: 0036897074     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.12.4000-4003.2002     Document Type: Article

References (18)

1. Arion, D., N. Kaushik, S. McCormick, G. Borkow, and M. Parniak. 1998. Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′-deoxythymidine (AZT): Increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 37:15908-15917.
2. Cohen, C. J., M. Sension, C. Farthing, M. Conant, S. Jacobson, J. Nadler, W. Verbiest, K. Hertogs, M. Ames, A. Rinehart, N. M. Graham, and the VIRA 3001 Study Team. 2002. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 16:1-10.
3. Delaugerre, C., M. Mouroux, A. Yvon-Groussin, A. Simon, F. Angleraud, J.-M. Huraux, H. Agut, C. Katlama, and V. Calvez. 2001. Prevalence and conditions of selection of E44D/A and V118I human immunodeficiency virus type 1 reverse transcriptase mutations in clinical practice. Antimicrob. Agents Chemother. 45:946-948.
4. Götte, M., D. Arion, M. A. Parniak, and M. A. Wainberg. 2000. The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis. J. Virol. 74:3579-3585.
5. Hertogs, K., S. Bloor, V. De Vroey, C. Van den Eynde, P. Dehertogh, A. Van Cauwenberge, M. Sturmer, T. M. Alcorn, S. Wegner, M. Van Houtte, V. Miller, and B. Larder. 2000. A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V. Antimicrob. Agents Chemother. 44:568-573.
6. Hollinger, F. B., J. W. Bremer, L. E. Myers, J. W. M. Gold, L. McQuay, and The NIH/NIAID/DAIDS/ACTG Virology Laboratories. 1992. Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group. J. Clin. Microbiol. 30:1787-1794.
7. Japour, A. J., D. L. Mayers, V. A. Johnson, D. R. Kuritzkes, L. A. Beckett, J. M. Arduino, J. Lane, R. J. Black, P. S. Reichelderfer, R.T. D'Aquila, C. S. Crumpacker, the RV-43 Study Group, and the AIDS Clinical Trials Group Virology Committee Resistance Working Group. 1993. A standardized peripheral blood mononuclear cell culture assay for the determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 37:1095-1101.
8. Kemp, S., C. Shi, S. Bloor, P. R. Harrigan, J. Mellors, and B. Larder. 1998. A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2′ ,3′-dideoxy-3′-thiacytidine. J. Virol. 72:5093-5098.
9. Kuritzkes, D., D. Shugarts, M. Bakhtiari, D. Poticha, J. Johnson, T. Gingeras, M. Kennedy, and J. Eron. 2000. Emergence of dual resistance to zidovudine and lamivudine after long-term treatment of human immunodeficiency virus type 1 (HIV-1) infection with zidovudine plus lamivudine. J. Acquir. Immune Defic. Syndr. 23:26-34.
10. Kuritzkes, D. R., J. B. Quinn, S. L. Benoit, D. L. Shugarts, A. Griffin, M. Bakhtiari, D. Poticha, J. J. Eron, M. A. Fallon, and M. Rubin. 1996. Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. AIDS 10:975-981.
11. Larder, B. A., S. D. Kemp, and P. R. Harrigan. 1995. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269:696-699.
12. Mellors, J. W., H. Z. Bazmi, R. Schinazi, B. M. Roy, Y. Hsiou, E. Arnold, J. Weir, and D. L. Mayers. 1995. Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates. Antimicrob. Agents Chemother. 39:1087-1092.
13. Meyer, P. R., S. E. Matsuura, A. G. So, and W. A. Scott. 1998. Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. Proc. Natl. Acad. Sci. USA 95:13471-13476.
14. Miller, V., A. N. Phillips, C. Rottman, S. Staszewski, R. Pauwels, K. Hertogs, M. P. de Bethun, S. D. Kemp, S. Bloor, P. R. Harrigan, and B. Larder. 1998. Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: Association with therapy failure. J. Infect. Dis. 177:1521-1532.
15. Nijhuis, M., R. Schuurman, D. deJong, R. VanLeeuwn, J. Lang, S. Danner, W. Keulen, T. deGroot, and C. A. B. Boucher. 1997. Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo. J. Infect. Dis. 176:398-405.
16. Precious, H., H. Gunthard, J. K. Wong, R. D'Aquila, V. A. Johnson, D. R. Kuritzkes, D. D. Richman, and A. Leigh-Brown. 2000. Multiple sites in HIV-1 reverse transcriptase associated with virological response to combination therapy. AIDS 14:31-36.
17. Romano, L., G. Venturi, S. Bloor, R. Harrigan, B. A. Larder, and M. Zazzi. 2002. Broad nucleoside analogue resistance implications for human immunodeficiency virus type 1 reverse-transcriptase mutations at codons 44 and 118. J. Infect. Dis. 185:898-904.
18. Tisdale, M., S. D. Kemp, N. R. Parry, and B. A. Larder. 1993. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. Natl. Acad. Sci. USA 90:5653-5656.